Soluble ST2 monitoring provides additional risk stratification for outpatients with decompensated heart failure;La monitorización de ST2 soluble proporciona una estratificación del riesgo adicional en pacientes ambulatorios con insuficiencia cardiaca descompensada

Revista Espanola de Cardiologia

Volumn 63, Issue 10, 2010, Pages 1171-1178

  Bayes Genis, Antoni ^a,b   Pascual Figal, Domingo ^c   Januzzi, James L ^d   Maisel, Alan ^e   Casas, Teresa ^c   Chávarri, Mariano Valdés ^c   Ordóñez Llanos, Jordi ^b,f  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

Heart failure; NT proBNP ST2; Prognosis

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; PROTEIN; SOLUBLE ST2 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL ARTICLE; CLINICAL DECISION MAKING; CONCENTRATION (PARAMETERS); DECOMPENSATED HEART FAILURE; DISEASE MARKER; DISEASE SEVERITY; HEART FAILURE; HEART TRANSPLANTATION; HOSPITAL ADMISSION; HUMAN; OUTPATIENT; RECEIVER OPERATING CHARACTERISTIC; RISK;

AGED; AREA UNDER CURVE; BIOLOGICAL MARKERS; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HEART TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; OUTPATIENTS; PEPTIDE FRAGMENTS; RECEPTORS, CELL SURFACE; REGRESSION ANALYSIS; RISK ASSESSMENT; ROC CURVE; STROKE VOLUME; TREATMENT OUTCOME;

EID: 78649291119     PISSN: 03008932     EISSN: 15792242     Source Type: Journal    
DOI: 10.1016/S0300-8932(10)70249-9     Document Type: Article

References (18)

1. E.O. Weinberg, M. Shimpo, G.W. De Keulenaer, C. MacGillivray, C. Tominaga, and S. Solomon Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction Circulation 106 2002 2961 2966
2. S. Sanada, D. Hakuno, L.J. Higgins, E.R. Schreiter, A.N.J. McEnzie, and R.T. Lee IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system J Clin Invest 117 2007 1538 1549
3. A.A. Chackerian, E.R. Oldham, E.E. Murphy, J. Schmitz, S. Pflanz, and R.A. Kastelein IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex J Immunol 179 2007 2551 2555
4. J.L. Januzzi Jr, W.F. Peacock, A.S. Maisel, C.U. Chae, R.L. Jesse, and A.L. Baggish Measurement of the interleukin family member ST2 in patients with acute dyspnea J Am Coll Cadiol 50 2007 607 613
5. D.A. Pascual-Figal, J. Ordoñez-Llanos, P.L. Tornel, R. Vázquez, T. Puig, and M. Valdés Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction J Am Coll Cardiol 54 2009 2174 2179
6. K.K. Ho, J.L. Pinsky, W.B. Kannel, and D. Levy The epidemiology of heart failure: the Framingham Study J Am Coll Cardiol 22 Suppl A 1993 A6 A13
7. D.A. Pascual-Figal, M. Domingo, T. Casas, I. Gich, J. Ordoñez-Llanos, and P. Martínez Usefulness of clinical and NT-proBNP monitoring for prognostic guidance in destabilized heart failure outpatients Eur Heart J 29 2008 1011 1018
8. K. Kuroiwa, H. Li, K. Tago, H. Iwahana, K. Yanagisawa, and N. Komatsu Construction of ELISA system to quantify human ST2 protein in sera of patients Hybridoma 19 2000 151 159
9. J.L. Januzzi Jr, R. Sakhuja, M. O'Donoghue, A.L. Baggish, S. Anwaruddin, and C.U. Chae Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department Arch Intern Med 166 2006 315 320
10. K. Oshikawa, K. Kuroiwa, K. Tago, H. Iwahana, K. Yanagisawa, and S. Ohno Elevated soluble ST2 protein levels in sera of patients with asthma with an acute exacerbation Am J Respir Crit Care Med 164 2001 277 281
11. K. Oshikawa, K. Kuroiwa, T. Tokunaga, T. Kato, S.I. Hagihara, and S.I. Tominaga Acute eosinophilic pneumonia with increased soluble ST2 in serum and bronchoalveolar lavage fluid Respir Med 95 2001 532 533
12. M. Brunner, C. Krenn, G. Roth, B. Moser, M. Dworschak, and E. Jensen-Jarolim Increased levels of soluble ST2 protein and IgG1 production in patients with sepsis and trauma Intensive Care Med 30 2004 1468 1473
13. E.O. Weinberg, M. Shimpo, S. Hurwitz, S. Tominaga, J.L. Rouleau, and R.T. Lee Identification of serum soluble ST2 receptor as a novel heart failure biomarker Circulation 107 2003 721 726
14. M. Löhning, A. Stroehmann, A.J. Coyle, J.L. Grogan, S. Lin, and J.C. Gutiérrez-Ramos T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function Proc Natl Acad Sci U S A 95 1998 6930 6935
15. J. Schmitz, A. Owyang, E. Oldham, Y. Song, E. Murphy, and T.K. McClanahan IL-33, an interleukin-1 -like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines Immunity 23 2005 479 490
16. R.W. Troughton, C.M. Frampton, T.G. Yandle, E.A. Espiner, M.G. Nicholls, and A.M. Richards Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations Lancet 355 2000 1126 1130
17. P. Jourdain, G. Jondeau, F. Funck, P. Gueffet, A. Le Helloco, and E. Donal Plasma brain natriuretic peptideguided therapy to improve outcome in heart failure (The STARS-BNP multicenter study) J Am Coll Cardiol 49 2007 1733 1739
18. M.S. Sabatine, D.A. Morrow, L.J. Higgins, C. MacGillivray, W. Guo, and C. Bode Complementary roles for biomarkers of biomechanical strain ST2 and N-Terminal Prohormone B-Type Natriuretic Peptide in patients with ST-elevation myocardial infarction Circulation 117 2008 1936 1944